.
MergerLinks Header Logo

Announced

Completed

Leaps by Bayer, Matrix-backed AyurMaya and Amgen Ventures led a $200m Series B funding round in ReCode Therapeutics.

Financials

Edit Data
Transaction Value£163m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pharmaceuticals

Private Equity

Venture Capital

United States

Private

Completed

Cross Border

Minority

drug delivery

Acquisition

Friendly

Synopsis

Edit

Leaps by Bayer, Matrix-backed AyurMaya and Amgen Ventures led a $200m Series B funding round in ReCode Therapeutics, a developer integrated genetic medicines company, with participation from Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Orbimed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Tekla Capital Management, Superstring Capital and NS Investment. “The ability to directly target specific organs and cells beyond the liver remains a key challenge for genetic medicines. At Leaps by Bayer, we strongly focus on finding breakthrough solutions that have the potential to make a meaningful difference for people with rare genetic diseases, and we believe ReCode is a unique company in our industry whose innovations have the potential to fundamentally shift an entire area of genetic medicine," Juergen Eckhardt, Leaps by Bayer CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US